194 related articles for article (PubMed ID: 19558958)
1. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.
Sanz-Viedma S; Torigian DA; Parsons M; Basu S; Alavi A
Rev Esp Med Nucl; 2009; 28(3):159-66. PubMed ID: 19558958
[No Abstract] [Full Text] [Related]
2. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET.
Núñez R; Kalapparambath A; Varela J
Rev Esp Med Nucl; 2007; 26(4):196-207. PubMed ID: 17662186
[TBL] [Abstract][Full Text] [Related]
3. Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.
Bertagna F; Evangelista L; Piccardo A; Bertoli M; Bosio G; Giubbini R; Orlando E; Treglia G
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):24-9. PubMed ID: 25312053
[TBL] [Abstract][Full Text] [Related]
4. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
5. Positive positron emission tomography/computed tomography scan and multiple pulmonary nodules: an unusual diagnosis.
Pacheco C; Cruz J; Ferreira L
Arch Bronconeumol; 2015 Jan; 51(1):48-9. PubMed ID: 24629761
[No Abstract] [Full Text] [Related]
6. Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings.
Houshmand S; Salavati A; Segtnan EA; Grupe P; Høilund-Carlsen PF; Alavi A
PET Clin; 2016 Jan; 11(1):65-84. PubMed ID: 26590445
[TBL] [Abstract][Full Text] [Related]
7. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection.
Bakheet SM; Saleem M; Powe J; Al-Amro A; Larsson SG; Mahassin Z
Clin Nucl Med; 2000 Apr; 25(4):273-8. PubMed ID: 10750966
[TBL] [Abstract][Full Text] [Related]
8. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5.
Chen CJ; Lee BF; Yao WJ; Cheng L; Wu PS; Chu CL; Chiu NT
AJR Am J Roentgenol; 2008 Aug; 191(2):475-9. PubMed ID: 18647920
[TBL] [Abstract][Full Text] [Related]
9. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity.
Schillaci O
Semin Nucl Med; 2012 Jul; 42(4):267-80. PubMed ID: 22681676
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
Czech N; Brenner W; Kampen WU; Henze E
Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
[No Abstract] [Full Text] [Related]
11. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG imaging: pitfalls and artifacts.
Abouzied MM; Crawford ES; Nabi HA
J Nucl Med Technol; 2005 Sep; 33(3):145-55; quiz 162-3. PubMed ID: 16145222
[TBL] [Abstract][Full Text] [Related]
13. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
14. Normal Patterns and Pitfalls of FDG Uptake in the Head and Neck.
Gray BR; Koontz NA
Semin Ultrasound CT MR; 2019 Oct; 40(5):367-375. PubMed ID: 31635764
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography for benign and malignant disease.
Visioni A; Kim J
Surg Clin North Am; 2011 Feb; 91(1):249-66. PubMed ID: 21184913
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CT.
Dong A; Wang Y; Lu J; Zuo C
Clin Nucl Med; 2016 Jul; 41(7):543-57. PubMed ID: 26975010
[TBL] [Abstract][Full Text] [Related]
18. Use of positron emission tomography in oncology.
Glaspy JA; Hawkins R; Hoh CK; Phelps ME
Oncology (Williston Park); 1993 Jul; 7(7):41-6, 49-50; discussion 50-2, 55. PubMed ID: 8347460
[TBL] [Abstract][Full Text] [Related]
19. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
